- Home
- GBDC vs VRDN Comparison
GBDC vs VRDN Comparison
Compare GBDC & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBDC | VRDN |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.2B |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | GBDC | VRDN |
|---|---|---|
| Price | $12.72 | $30.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $14.17 | ★ $41.42 |
| AVG Volume (30 Days) | ★ 2.5M | 1.5M |
| Earning Date | 02-04-2026 | 02-26-2026 |
| Dividend Yield | ★ 12.12% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.24 | N/A |
| Revenue | ★ $857,084,000.00 | $70,789,000.00 |
| Revenue This Year | N/A | $26,080.80 |
| Revenue Next Year | N/A | $2.07 |
| P/E Ratio | $10.35 | ★ N/A |
| Revenue Growth | 9.80 | ★ 23340.07 |
| 52 Week Low | $12.28 | $9.90 |
| 52 Week High | $16.01 | $34.29 |
Technical Indicators
Market Signals| Indicator | GBDC | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 38.35 | 40.41 |
| Support Level | $12.36 | $28.92 |
| Resistance Level | $12.98 | $30.75 |
| Average True Range (ATR) | 0.28 | 1.47 |
| MACD | -0.07 | -0.40 |
| Stochastic Oscillator | 28.81 | 21.67 |
Price Performance
Historical ComparisonAbout GBDC Golub Capital BDC Inc.
Golub Capital BDC Inc. is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in U.S. middle-market companies. It also invests in second-lien and subordinated loans, warrants, and minority equity securities in U.S. middle-market companies. The company generally invests in securities rated below investment grade by independent rating agencies, or those that would be rated below investment grade if evaluated. The company operates in the USA, Canada, and other countries, with the majority of its revenue coming from the USA.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).